Track Chinook Therapeutics's long-term debt ($30M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2023), KDNY shows a long-term debt of $30M. That compares with $37M in the prior-year period — down 20.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, KDNY's long-term debt is now $30M (was $37M) — a 20.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Chinook Therapeutics is outperforming or lagging.
Tracking KDNY's long-term debt over time shows whether Chinook Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $30M That compares with $37M in the prior-year period — down 20.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Chinook Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $30M) with ownership activity and broader fundamentals.
Chinook Therapeutics's long-term debt is $30M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.